Related Experiment Video
Updated: Jun 17, 2026
07:05
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
Xeomin: an innovative new botulinum toxin type A.
1Merz Pharmaceuticals GmbH, Potsdam, Germany. Juergen.Frevert@merz.de
European Journal of Neurology
|December 17, 2009
Summary
Botulinum toxin type A (BoNT/A) is used to treat muscle overactivity. A new formulation, Xeomin, is free of complexing proteins, offering a pure neurotoxin for therapeutic effects.
Area of Science:
- Neurology
- Pharmacology
Background:
- Botulinum toxin type A (BoNT/A) effectively treats muscle and nerve overactivity disorders.
- Complexing proteins in BoNT/A formulations may have immunostimulating activity and are not required for neurotoxin stability.
- These proteins dissociate at physiological pH and do not influence neurotoxin spread.
Purpose of the Study:
- To highlight Xeomin as a unique botulinum toxin formulation free from complexing proteins.
- To explain the mechanism of action of Xeomin in inhibiting neuromuscular transmission.
Main Methods:
- Xeomin is a purified neurotoxin, stable at room temperature.
- It is administered via direct intramuscular injection.
- The mechanism involves binding to motor nerve terminals, internalization, and cleavage of SNAP-25.
Main Results:
- Xeomin inhibits local neuromuscular cholinergic transmission, leading to focal muscle weakness.
- Cleavage of SNAP-25 prevents acetylcholine secretion, causing muscle paralysis.
- Clinical effects manifest within 24-72 hours, peaking at 4-6 weeks, and lasting for months.
Conclusions:
- Xeomin provides a pure BoNT/A formulation without potentially immunostimulating complexing proteins.
- Its targeted mechanism of action offers a therapeutic option for conditions involving muscle overactivity.
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:22Botulism
Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...